There is a version of this story where a man walks into a clinic, gets his blood drawn, sits down with a physician who knows what he's looking at, and walks out with a treatment plan built around him. That version exists. It's just not the version being sold to you in a sidebar ad promising "More Energy. More Drive. Prescribed Online in 10 Minutes."

The online testosterone boom is one of the fastest-growing corners of American healthcare, and most men wading into it have no idea what they're actually buying. They think they're buying a fix. What a lot of these operations are actually selling is a subscription — one that works best, from a revenue standpoint, when you can never get off it.

We think you should understand exactly how the machine works before you decide whether to feed it. Not because testosterone therapy is evil — for men with genuine, clinically diagnosed hypogonadism it can be legitimate, physician-supervised, life-changing medicine. But because the business model of the direct-to-consumer clinic and the physiology of your own endocrine system are pulling in the same direction, and that direction is lifetime dependence. When the profit motive and the biology both point at the same door, you should at least know what's on the other side of it before you walk through.

The market didn't grow. It was grown.

Injectable testosterone prescriptions roughly doubled in the United States between 2019 and 2025, and the testosterone therapy market is being projected toward $2.5 billion. A 2023 analysis counted 223 online testosterone clinics operating in the U.S.; by one reporting count, more than 325 additional clinics opened after early 2024. That is not a patient population that suddenly got sicker. That is an industry that figured out how to manufacture demand.

Here's the tell. The men driving a huge share of this growth are not the frail 70-year-olds you'd expect from a "hormone deficiency" story. A large and growing slice are younger and middle-aged men who saw an ad, took a quiz, and got told they might have "Low T." The condition got marketed before the patients got diagnosed. That's the reverse of how medicine is supposed to work, and it's exactly how a subscription business is supposed to work.

The 10-minute diagnosis is the product

If you want to understand a business, look at what it's willing to skip.

Researchers ran a "secret shopper" study on direct-to-consumer testosterone platforms and published it in JAMA Internal Medicine in 2023. They sent in a standardized fake patient: a 34-year-old man complaining of low energy and libido, who explicitly said he wanted to father children in the future. His actual bloodwork was normal — a total testosterone of 675 ng/dL, comfortably inside the reference range.

Six of the seven platforms offered him testosterone therapy anyway.

Read that again. A man with normal testosterone, who said out loud that he wanted kids, was offered a treatment that is well-documented to suppress fertility — by roughly 86% of the platforms tested. The same study found that most platforms had no total-testosterone threshold at all for starting treatment, that only three of six even discussed the effect on fertility, and that a majority never mentioned polycythemia — the thickening of the blood that's one of testosterone therapy's most monitored risks.

This is not sloppiness. Sloppiness is random. This is a system optimized to convert a visitor into a prescription with the fewest possible obstacles, because every step that could result in "actually, you don't need this" is a step that kills a sale. The physical exam that a legitimate workup requires? Friction. The insistence on two separate morning blood tests showing genuinely low levels plus real symptoms, the way the actual clinical guidelines recommend? Friction. The honest conversation about what this does to your fertility and your blood? Friction. Every piece of careful medicine is, on a spreadsheet, a leak in the funnel.

Even the diagnostic goalposts help. There is no single agreed number for "low." The American Urological Association draws the line at under 300 ng/dL. The Endocrine Society uses under 264. The European Association of Urology uses under 350. When the definition of the disease is a range you can pick from, the marketing writes itself — and a man who is "normal" by one standard is a "patient" by another.

Now the part they really don't lead with

Here's where the business model and your biology shake hands.

When you take exogenous testosterone — testosterone from outside your body — your brain notices. Your hypothalamus and pituitary run a feedback loop called the HPG axis, and its whole job is to keep your hormones in balance. When it detects plenty of testosterone in your blood, it does the logical thing: it tells your own factories to stop. It dials down the signals (LH and FSH) that tell your testicles to produce testosterone and sperm. Supply from the outside; shutdown on the inside.

This is not a fringe claim or a supplement-company scare tactic. It's basic, textbook endocrinology, and it's the exact mechanism doctors rely on. The suppression of intratesticular testosterone is profound — the local hormone environment your sperm production depends on can collapse, which is why testosterone was actually studied as a male contraceptive. In those studies, sperm counts dropped low enough to prevent pregnancy in the large majority of men. That's the point. That's what it does.

Come off it, and for most men the system recovers — but on its own timeline, not yours. In the contraception research, sperm concentrations returned to the normal fertile range in about 67% of men by six months, 90% by a year, and effectively all by two years. For men who'd been on higher doses for longer — the anabolic-steroid pattern that some aggressive clinics drift toward — recovery averaged closer to a year, with some hormonal markers taking a year and a half or more to normalize. Longer time on, higher doses, older age, and any pre-existing testicular weakness all stretch that number out.

So put yourself in the shoes of a 45-year-old who signed up after one borderline blood test and an online quiz. Six months in, his own production is suppressed. His baseline — whatever it was — is now buried under a shutdown that takes months to reverse if he manages it carefully. Quitting doesn't feel like quitting a vitamin. It feels like crashing, because his body's own supply is offline and hasn't spun back up yet. The low energy and low mood that sent him looking in the first place come roaring back, worse, because now they're withdrawal.

What does he do? He refills. Of course he refills.

That is the whole model in one sentence: the treatment creates the condition that makes the treatment feel necessary. No villain required. No one has to twist a mustache. A business that profits from monthly refills, a diagnostic process engineered to say yes, and a hormone that shuts down your own production and is unpleasant to stop — those three things don't need to conspire. They just need to exist in the same place at the same time. And right now, in an ad targeted at you, they do.

Follow the recurring revenue

Look at how these companies are actually priced and you'll see what they're optimizing for. The subscription model runs anywhere from around $100 to several hundred dollars a month, billed on autopilot. Some send an at-home test kit; some have been documented prescribing with barely any testing at all. The valuable customer, in this model, is not the man who gets better and leaves. The valuable customer is the man who is on it forever.

Compare the incentives. A legitimate physician managing genuine hypogonadism has every reason to test thoroughly, dose conservatively, monitor your blood, and talk you out of it if you don't need it — because their job is your health and their license is on the line. A funnel-optimized clinic has every reason to get you to "yes" fast, keep the dose high enough that you feel a difference, and never make quitting easy — because their job is your recurring payment. Same molecule. Opposite motives. The molecule doesn't care which one is prescribing it; your endocrine system responds identically either way. The only variable that protects you is who's holding the prescription pad and what they get paid for.

What this is actually about

We're not here to tell you your energy, your drive, and your strength don't matter at 40 and beyond. They're the entire reason this company exists. We're here because we think the men most likely to get taken by this are exactly the men we build for: guys who feel a step slower than they used to, who are tired of being tired, and who are being offered a needle by a website that has never met them and gets paid every month they stay on it.

There's a difference between raising what your body makes and replacing it. Supporting your own production — through training, sleep, bringing your bodyfat down, fixing the nutritional holes, and yes, honest supplementation formulated for men our age — works with the HPG axis instead of switching it off. It's the entire reason we built Adaptophen the way we did: to give an older athlete's own hormonal machinery what it needs to run, not to override it and take it offline. That's a different philosophy from a prescription that floods your system in week one and lets your factories rust. It's slower. It asks something of you. It also doesn't hand a subscription company the keys to your own hormones — and it doesn't leave you facing a months-long shutdown the day you decide to stop.

Let's be straight about what that is and isn't, because being straight is the whole point of this article. A supplement that supports your natural production is not the same thing as exogenous testosterone, and we'd never pretend it is. If your levels are truly, clinically low, a support formula is not going to replace what a properly supervised physician can do — and we'll tell you that to your face. What it is good for is the far larger group of men who feel a step slow, whose numbers aren't rock-bottom, and who are one targeted ad away from being talked onto a needle they may never get off. For that man, working with his own biology first isn't the consolation prize. It's the smarter opening move.

And if your testosterone genuinely is clinically low — really, measurably, symptomatically low — then you deserve a real doctor. Someone who tests you properly, more than once, in the morning. Someone who examines you, knows your history, tells you the truth about your fertility and your blood, monitors you over time, and has no financial reason to keep you on it a single month longer than you need. That person exists. Find that. The bar for putting an exogenous hormone into your body for the rest of your life should be a lot higher than a ten-minute quiz and a credit card on file.

Ask the hard question before you start, because it's a lot harder to ask it six months in: if this works, when do I get off it — and who profits if I never do?

If working with your own biology first sounds like the smarter opening move, that's exactly what we built Adaptophen for. Same honesty, no subscription trap — just support for the machinery you already own.

This article is for general education and is not medical advice. Testosterone replacement therapy is a legitimate, effective treatment for clinically diagnosed hypogonadism when it's supervised by a qualified physician. The concerns raised here are about business practices and diagnostic shortcuts in parts of the direct-to-consumer market — not about the medicine itself, and not about the many men who need and benefit from properly managed care. If you have symptoms you're worried about, get evaluated by a licensed clinician who tests thoroughly and has no stake in your answer.